Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Work In Process (2016 - 2024)

Historic Work In Process for Astrazeneca (AZNCF) over the last 10 years, with Q4 2024 value amounting to $2.3 billion.

  • Astrazeneca's Work In Process fell 184.95% to $2.3 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $2.3 billion, marking a year-over-year decrease of 184.95%. This contributed to the annual value of $2.3 billion for FY2024, which is 184.95% down from last year.
  • According to the latest figures from Q4 2024, Astrazeneca's Work In Process is $2.3 billion, which was down 184.95% from $2.3 billion recorded in Q4 2023.
  • Astrazeneca's 5-year Work In Process high stood at $5.2 billion for Q4 2021, and its period low was $1.3 billion during Q4 2020.
  • In the last 5 years, Astrazeneca's Work In Process had a median value of $2.3 billion in 2024 and averaged $2.6 billion.
  • As far as peak fluctuations go, Astrazeneca's Work In Process skyrocketed by 29188.58% in 2021, and later tumbled by 6426.38% in 2022.
  • Over the past 5 years, Astrazeneca's Work In Process (Quarter) stood at $1.3 billion in 2020, then skyrocketed by 291.89% to $5.2 billion in 2021, then plummeted by 64.26% to $1.9 billion in 2022, then rose by 24.73% to $2.3 billion in 2023, then decreased by 1.85% to $2.3 billion in 2024.
  • Its Work In Process was $2.3 billion in Q4 2024, compared to $2.3 billion in Q4 2023 and $1.9 billion in Q4 2022.